Skip to main navigation Skip to search Skip to main content

The diagnostic utility of serum ferritin. Estimation in patients with primary hepatocellular carcinoma

  • S. O. Ola
  • , A. O. Akanji*
  • , E. A. Ayoola
  • *Corresponding author for this work
  • Kuwait University

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Serum hepatitis B surface antigen (HBsAg) status and ferritin levels were measured in 3 groups of subjects: Group A (n = 14) with chronic non-neoplastic liver disease (CNLD), Group B (n = 14) with primary hepatocellular carcinoma (PHC) and Group C (n = 14) comprising healthy matched controls without liver disease. Serum ferritin values were lowest in Group C, intermediate in Group A and highest in the Group B patients (all p < 0.05). About 79% of the patients with PHC, 43% of those with CNLD and none (0%) of the healthy controls, had hyperferritinaemia (serum ferritin >400 ng/ml). Hyperferritinaemia and HBsAg positivity coexisted in 15% and 73% of the patients with CNLD and PHC, respectively. Hyperferritinaemia and HBsAg were significantly positively related in the patients with PHC (χ2 5.09, p < 0.05). The predictive indices of hyperferritinaemia in chronic liver disease appeared superior for PHC than for CNLD, and became somewhat enhanced with coexisting HBsAg positivity. These results suggest that serum ferritin could be useful as a tumour marker for PHC in patients with established chronic liver disease.

Original languageEnglish
Pages (from-to)302-304
Number of pages3
JournalTropical and Geographical Medicine
Volume47
Issue number6
StatePublished - 1995

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • ferritin
  • hepatitis B surface antigens
  • hepatocellular carcinoma
  • liver diseases
  • Nigeria
  • tumour markers

Fingerprint

Dive into the research topics of 'The diagnostic utility of serum ferritin. Estimation in patients with primary hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this